Advertisement
EDIT vs VRTX
Which Stock Would AI Choose? Editas Medicine (EDIT) vs. Vertex Pharmaceuticals (VRTX) Stock Comparison
Key Takeaways
- Editas Medicine (EDIT) is a clinical-stage gene-editing developer with no approved products, while Vertex Pharmaceuticals (VRTX) is a profitable large-cap biopharmaceutical company with a dominant cystic fibrosis (CF) franchise.
- In recent quarters, VRTX has generated billions in quarterly revenue and stable earnings, whereas EDIT remains essentially pre-revenue beyond modest collaboration income and continues to post net losses.
- Relative performance and market positioning diverge sharply: VRTX offers established cash flow and a maturing pipeline, while EDIT carries high-risk, high-optionality exposure tied to its early-stage in vivo editing program, EDIT-401.
- Tickeron AI Verdict: Based on trend consistency, financial stability, and near-term catalysts, Tickeron's AI would currently favor VRTX over EDIT in this stock comparison.
- For deeper context, explore EDIT Major News and EDIT Today's Price Move, as well as VRTX Major News and VRTX Today's Price Move.
- To see how automated strategies are positioning for the current market, explore Trending AI Robots.
Introduction
This stock comparison examines two very different names in the biotechnology space: EDIT, a clinical-stage CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) gene-editing company, and VRTX, a diversified, profitable biopharmaceutical giant best known for its cystic fibrosis treatments. Investors weighing these tickers are effectively comparing an early-stage, catalyst-driven opportunity against an established, cash-generating market leader. The comparison is most relevant to traders and investors seeking to understand how relative performance, risk profiles, and market positioning differ between a speculative biotech and a large-cap franchise, and to those evaluating which stock an AI-driven framework might currently favor.
EDIT Overview and Recent Performance
Editas Medicine is a clinical-stage genome-editing company built on CRISPR technology. It has no approved products and generates limited revenue from collaboration and research agreements, so its valuation is driven largely by pipeline progress rather than current earnings. In late 2024, the company discontinued its lead reni-cel program after failing to secure a commercial partner, reduced its workforce by roughly 65%, and pivoted its focus toward in vivo (inside-the-body) gene editing. This restructuring has lowered operating costs and narrowed losses in recent quarters, with the company reporting a smaller-than-expected fourth-quarter loss and collaboration revenue ahead of consensus estimates.
In recent weeks, sentiment around EDIT has centered on its lead in vivo candidate, EDIT-401, a one-time gene-editing therapy designed to reduce LDL cholesterol (low-density lipoprotein, or "bad" cholesterol). Preclinical data have shown durable LDL-C reductions, and the company is targeting an Investigational New Drug (IND) application filing by mid-2026. However, EDIT remains several years from potential commercialization, with a modest cash position funding operations into 2027 and elevated execution risk typical of pre-clinical biotechs.
VRTX Overview and Recent Performance
Vertex Pharmaceuticals is a large-cap biopharmaceutical company with a dominant position in cystic fibrosis, treating a substantial share of eligible patients worldwide through products led by Trikafta/Kaftrio. The company is profitable, generates billions in quarterly revenue, and reported double-digit year-over-year sales growth in recent quarters, supported by the launch of Alyftrek, its next-generation CF triple-combination therapy.
Recent market activity around VRTX has reflected mixed sentiment. While core CF sales have remained solid and earnings have generally beaten estimates, newer product launches—Journavx, a non-opioid pain medicine, and Casgevy, a gene-editing therapy for sickle cell disease and beta thalassemia—have seen slower-than-expected initial uptake, weighing on the stock at times. Investors are also tracking pipeline catalysts in kidney disease, including povetacicept for IgA nephropathy, and earlier-stage programs in type 1 diabetes. VRTX's relative performance has lagged its industry over recent months even as its underlying business remains stable and cash-generative.
Trending AI Robots
Tickeron maintains hundreds of AI trading bots that collectively trade thousands of different tickers across varied strategies, timeframes, and risk profiles. Because not every bot suits every market condition, Tickeron curates the best-performing and most relevant strategies into a dedicated Trending AI Robots section. This shortlist highlights bots whose statistics, trading styles, and performance align with the current market environment, helping traders filter signal from noise. Each bot differs in approach, timeframe, and the set of tickers it trades, so no single strategy fits all investors. Explore the Trending AI Robots page to review the curated selection and identify approaches suited to your own trading objectives.
Head-to-Head Comparison
The core contrast in this stock comparison is maturity versus optionality. VRTX has an established business model built on a durable CF franchise, steady free cash flow, and multiple growth drivers, but its newer product launches have yet to scale as quickly as the market hoped, creating near-term pressure on sentiment. EDIT, by contrast, has a concentrated, pre-clinical profile where a single candidate—EDIT-401—can drive outsized moves on data readouts, but where dilution, regulatory, and execution risks are materially higher.
Growth drivers also differ. VRTX's expansion depends on commercial execution across pain, gene therapy, and kidney-disease franchises, while EDIT's trajectory hinges almost entirely on advancing in vivo editing toward the clinic. On risk factors, EDIT faces liquidity and clinical-trial risk, whereas VRTX faces slower product-ramp and pipeline-readout risk. Market sentiment reflects these differences: VRTX is viewed as a high-quality, lower-volatility name trading below some analysts' price targets, while EDIT is seen as a speculative turnaround with wide-ranging analyst expectations.
Tickeron AI Verdict
Weighing observable factors such as trend consistency, financial stability, relative positioning, and the quality of near-term catalysts, Tickeron's AI would currently favor VRTX over EDIT. The framework tends to reward VRTX's established revenue base, profitability, and diversified pipeline over EDIT's pre-revenue, single-candidate profile, which carries greater uncertainty. While EDIT offers higher speculative upside if EDIT-401 succeeds, its risk-adjusted profile and less consistent price trend place it behind VRTX on a probabilistic basis in the current market environment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EDIT is a StrongBuy and VRTX is a Buy.
Aroon Indicator for EDIT shows an upward move is likely
EDIT's Aroon Indicator triggered a bullish signal on November 11, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 154 similar instances where the Aroon Indicator showed a similar pattern. In 128 of the 154 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +7.84% 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in 182 of 227 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EDIT as a result. In 78 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for EDIT turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 44 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
EDIT moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for EDIT moved below the 200-day moving average on November 09, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
EDIT broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 30 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.749) is normal, around the industry mean (3.498). P/E Ratio (-3.894) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (5.855) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 71 (best 1 - 100 worst), indicating slightly worse than average price growth. EDIT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
VRTX in upward trend: 10-day moving average broke above 50-day moving average on October 30, 2026
The 10-day moving average for VRTX crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 74%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on VRTX as a result. In 56 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 65%.
The Moving Average Convergence Divergence (MACD) for VRTX just turned positive on October 20, 2026. Looking at past instances where VRTX's MACD turned positive, the stock continued to rise in 41 of 59 cases over the following month. The odds of a continued upward trend are 69%.
VRTX moved above its 50-day moving average on October 28, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +1.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where VRTX advanced for three days, in 235 of 368 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
The Aroon Indicator entered an Uptrend today. In 174 of 291 cases where VRTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 60%.
Bearish Trend Analysis
The 10-day RSI Indicator for VRTX moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 43 similar instances where the indicator moved out of overbought territory. In 26 of the 43 cases, the stock moved lower in the following days. This puts the odds of a move lower at 60%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 34 of 63 cases where VRTX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 54%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VRTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 43%.
VRTX broke above its upper Bollinger Band on October 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 13 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 26 (best 1 - 100 worst), indicating outstanding price growth. VRTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 39 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 41 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.848) is normal, around the industry mean (3.498). P/E Ratio (31.605) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (1.939) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (10.449) is also within normal values, averaging (440.869).
EDIT | VRTX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 73 | 33 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 53 Fair valued | 91 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 13 | |
SMR RATING 1..100 | 99 | 41 | |
PRICE GROWTH RATING 1..100 | 71 | 26 | |
P/E GROWTH RATING 1..100 | 30 | 39 | |
SEASONALITY SCORE 1..100 | 85 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
EDIT's Valuation (53) in the Biotechnology industry is somewhat better than the same rating for VRTX (91). This means that EDIT’s stock grew somewhat faster than VRTX’s over the last 12 months.
VRTX's Profit vs Risk Rating (13) in the Biotechnology industry is significantly better than the same rating for EDIT (100). This means that VRTX’s stock grew significantly faster than EDIT’s over the last 12 months.
VRTX's SMR Rating (41) in the Biotechnology industry is somewhat better than the same rating for EDIT (99). This means that VRTX’s stock grew somewhat faster than EDIT’s over the last 12 months.
VRTX's Price Growth Rating (26) in the Biotechnology industry is somewhat better than the same rating for EDIT (71). This means that VRTX’s stock grew somewhat faster than EDIT’s over the last 12 months.
EDIT's P/E Growth Rating (30) in the Biotechnology industry is in the same range as VRTX (39). This means that EDIT’s stock grew similarly to VRTX’s over the last 12 months.
| EDIT | VRTX | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 60% |
| Stochastic ODDS (%) | 2 days ago 77% | 2 days ago 54% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 65% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 69% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 42% |
| TrendMonth ODDS (%) | 2 days ago 89% | 2 days ago 68% |
| Advances ODDS (%) | 4 days ago 80% | 4 days ago 64% |
| Declines ODDS (%) | 2 days ago 90% | 2 days ago 43% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 51% |
| Aroon ODDS (%) | 2 days ago 83% | 2 days ago 60% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
EDIT’s FA Score shows that 1 FA rating(s) are green while VRTX’s FA Score has 2 green FA rating(s).
- EDIT’s FA Score: 1 green, 4 red.
- VRTX’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
EDIT’s TA Score shows that 3 TA indicator(s) are bullish while VRTX’s TA Score has 6 bullish TA indicator(s).
- EDIT’s TA Score: 3 bullish, 6 bearish.
- VRTX’s TA Score: 6 bullish, 4 bearish.
Price Growth
EDIT (@Biotechnology) experienced а -12.50% price change this week, while VRTX (@Biotechnology) price change was -0.37% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +11.66%. For the same industry, the average monthly price growth was +1.65%, and the average quarterly price growth was -13.40%.
Reported Earning Dates
EDIT is expected to report earnings on Feb 25, 2027.
VRTX is expected to report earnings on Feb 09, 2027.
Industries' Descriptions
@Biotechnology (+11.66% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
VRTX and
Correlation & Price change
A.I.dvisor indicates that over the last year, VRTX has been loosely correlated with RPRX. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if VRTX jumps, then RPRX could also see price increases.
| Ticker / NAME | Correlation To VRTX | 1D Price Change % | ||
|---|---|---|---|---|
| VRTX | 100% | -0.16% | ||
| RPRX - VRTX | 49% Loosely correlated | +0.81% | ||
| INCY - VRTX | 49% Loosely correlated | +1.64% | ||
| BMRN - VRTX | 45% Loosely correlated | +2.10% | ||
| EDIT - VRTX | 44% Loosely correlated | -4.99% | ||
| REGN - VRTX | 43% Loosely correlated | +4.73% | ||
More | ||||